France Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Opportunity Analysis and Industry Forecast, 2023-2032
The France Radiopharmaceuticals Market is a quickly expanding, specialized company with an estimated market value of EUR8.4 billion in 2020. Radiopharmaceuticals are drugs which contain radioactive aspects and have both analysis and also healing abilities. These medications are used primarily to detect different conditions in the body, such as diagnosing cancer cells. The most usual kinds of radiopharmaceuticals utilized in France are Technetium-99m, Fluorine-18, Iodine I, Gallium-68, as well as others. The radiopharmaceuticals market is categorized into applications (cancer cells, cardiology, as well as others), kind (diagnostic/therapeutic), and also end individual (hospitals/clinics clinical imaging centers, and others).
The development of the France radiopharmaceuticals market is mainly driven by the rising prevalence of cancer cells and also cardiology, as well as technological improvements in the health care field. Additionally, the boosting demand for cost-efficient and also specific medical diagnosis and the boosting number of public and personal financial investments in medical imaging are important elements driving the market. Additionally, the rising need for nuclear medicine procedures with radiopharmaceuticals is developing market growth opportunities.
The France radiopharmaceuticals market is dealing with restrictions such as the high cost of scientific tests, trade obstacles, and also financial restraints. Additionally, the demand for radiation safety measures and operational restrictions are hindering the development of the France radiopharmaceuticals market.
With the assistance of brand-new modern technologies, the radiopharmaceuticals market is being changed. Because of this, the advancement of brand-new radiopharmaceutical representatives are becoming extra cost-efficient and also efficient. Additionally, many brand-new innovations are taking place in the health care sector such as individualized medicine as well as the enhancing demand for innovative imaging methods. All of this is producing market possibilities.
The affordable rivalry is solid in the France radiopharmaceuticals market because of the expanding variety of players, along with the presence of international business. The negotiating power of consumers is additionally high as there is a vast array of services and products readily available. There is also excellent bargaining power from distributors as a result of minority resources offered for manufacturing as well as the visibility of strong players out there. The risk from replacements is moderate as the primary use of radiopharmaceuticals is for analysis and therapeutic functions in the healthcare industry. There is additionally modest risk from brand-new participants as the expense of entrance is fairly high due to the high rate of examinations, scientific trials, and regulative approvals.
The future of the France radiopharmaceuticals market is expected to be driven by the raising number of federal government efforts such as the introduction of health care infrastructures, promotional activities, aids, and also initiatives to lower management costs. Additionally, the growing R&D in the pharma market and also technological improvements are expected to fuel the market development. New growths in the distribution of medicine, such as oral and also inhalation types, will produce a lot more opportunities for radiopharmaceuticals. Furthermore, there is enhancing need for individualized medications and also the introduction of artificial intelligence and also machine learning in healthcare is likewise driving the market.
The France radiopharmaceuticals market has great possible for growth as a result of the increasing number of medical trials, the accessibility of innovative techniques, and also the inexpensive of manufacturing. Furthermore, the rising awareness of radiopharmaceuticals, the expanding number of healthcare infrastructures, and also the raising need for personalized medications are developing brand-new development possibilities. Additionally, the fostering of polymerase chain reaction (PCR)- based nucleic acid testing is positioned to sustain the market in the future.
The regulating bodies such as HAS, ANSM, MRT as well as Cerba has laid out strict guidelines on the manufacturing as well as use of radiopharmaceuticals in France. The regulations remain in area to ensure the quality as well as safety and security of the radiopharmaceuticals produced as well as to guarantee the risk-free circulation and disposal of the radioactive waste. In addition, the license charges as well as scientific trial guidelines additionally require to be complied with it.
The France radiopharmaceuticals market is additional segmented based upon radioisotope (Technetium-99m, Fluorine-18, Iodine-I, Gallium-68, Others), application (Cancer cells, Cardiology, Others), kind (Diagnostic, Healing) and also end customers (Hospitals/Clinics, Medical Imaging Centers, Others). The most commonly made use of radioisotope for radiopharmaceuticals in France is Technetium-99m and the primary end-user section is health centers as well as facilities.
Key Benefits For Stakeholders
Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
Analyze the key strategies adopted by major market players in france radiopharmaceuticals market.
Assess and rank the top factors that are expected to affect the growth of france radiopharmaceuticals market.
Top Player positioning provides a clear understanding of the present position of market players.
Detailed analysis of the france radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
Identify key investment pockets for various offerings in the market.
New Product Development/ Product Matrix of Key Players
Patient/epidemiology data at country, region, global level
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
SWOT Analysis
Key Market Segments
By Type
Diagnostic
Therapeutic
By End User
Hospitals and clinics
Medical Imaging centers
Others
By Radioisotope
Fluorine 18
Iodine I
Gallium 68
Others
Technetium 99m
By Application
Cancer
Cardiology
Others
Key Market Players
Progenics Pharmaceuticals
Bracco Diagnostics
Covidien
Jubilant Pharma
IBA Molecular
Curium Pharma
GE Healthcare
Cardinal Health
Novartis
Lantheus Medical Imaging
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits to the Stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Impacting Factors
- 3.2.2. Top Investment Pockets
- 3.3. Porter’s Five Forces Analysis
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: FRANCE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
- 4.1. Overview
- 4.1.1. Market Size and Forecast, By Radioisotope
- 4.2. Technetium 99m
- 4.3. Fluorine 18
- 4.4. Iodine I
- 4.5. Gallium 68
- 4.6. Others
- CHAPTER 5: FRANCE RADIOPHARMACEUTICALS MARKET, BY APPLICATION
- 5.1. Overview
- 5.1.1. Market Size and Forecast, By Application
- 5.2. Cancer
- 5.3. Cardiology
- 5.4. Others
- CHAPTER 6: FRANCE RADIOPHARMACEUTICALS MARKET, BY TYPE
- 6.1. Overview
- 6.1.1. Market Size and Forecast, By Type
- 6.2. Diagnostic
- 6.3. Therapeutic
- CHAPTER 7: FRANCE RADIOPHARMACEUTICALS MARKET, BY END USER
- 7.1. Overview
- 7.1.1. Market Size and Forecast, By End User
- 7.2. Hospitals and clinics
- 7.3. Medical Imaging centers
- 7.4. Others
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. Company 1
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. Company 2
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
- 9.3. Company 3
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
- 9.4. Company 4
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
- 9.5. Company 5
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
- 9.6. Company 6
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
- 9.7. Company 7
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
- 9.8. Company 8
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
- 9.9. Company 9
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
- 9.10. Company 10
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments
- LIST OF TABLES
- TABLE 01. FRANCE RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
- TABLE 02. FRANCE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 03. FRANCE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 04. FRANCE RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 05. COMPANY 1: KEY EXECUTIVES
- TABLE 06. COMPANY 1: COMPANY SNAPSHOT
- TABLE 07. COMPANY 1: OPERATING SEGMENTS
- TABLE 08. COMPANY 1: PRODUCT PORTFOLIO
- TABLE 09. COMPANY 1: KEY STRATERGIES
- TABLE 10. COMPANY 2: KEY EXECUTIVES
- TABLE 11. COMPANY 2: COMPANY SNAPSHOT
- TABLE 12. COMPANY 2: OPERATING SEGMENTS
- TABLE 13. COMPANY 2: PRODUCT PORTFOLIO
- TABLE 14. COMPANY 2: KEY STRATERGIES
- TABLE 15. COMPANY 3: KEY EXECUTIVES
- TABLE 16. COMPANY 3: COMPANY SNAPSHOT
- TABLE 17. COMPANY 3: OPERATING SEGMENTS
- TABLE 18. COMPANY 3: PRODUCT PORTFOLIO
- TABLE 19. COMPANY 3: KEY STRATERGIES
- TABLE 20. COMPANY 4: KEY EXECUTIVES
- TABLE 21. COMPANY 4: COMPANY SNAPSHOT
- TABLE 22. COMPANY 4: OPERATING SEGMENTS
- TABLE 23. COMPANY 4: PRODUCT PORTFOLIO
- TABLE 24. COMPANY 4: KEY STRATERGIES
- TABLE 25. COMPANY 5: KEY EXECUTIVES
- TABLE 26. COMPANY 5: COMPANY SNAPSHOT
- TABLE 27. COMPANY 5: OPERATING SEGMENTS
- TABLE 28. COMPANY 5: PRODUCT PORTFOLIO
- TABLE 29. COMPANY 5: KEY STRATERGIES
- TABLE 30. COMPANY 6: KEY EXECUTIVES
- TABLE 31. COMPANY 6: COMPANY SNAPSHOT
- TABLE 32. COMPANY 6: OPERATING SEGMENTS
- TABLE 33. COMPANY 6: PRODUCT PORTFOLIO
- TABLE 34. COMPANY 6: KEY STRATERGIES
- TABLE 35. COMPANY 7: KEY EXECUTIVES
- TABLE 36. COMPANY 7: COMPANY SNAPSHOT
- TABLE 37. COMPANY 7: OPERATING SEGMENTS
- TABLE 38. COMPANY 7: PRODUCT PORTFOLIO
- TABLE 39. COMPANY 7: KEY STRATERGIES
- TABLE 40. COMPANY 8: KEY EXECUTIVES
- TABLE 41. COMPANY 8: COMPANY SNAPSHOT
- TABLE 42. COMPANY 8: OPERATING SEGMENTS
- TABLE 43. COMPANY 8: PRODUCT PORTFOLIO
- TABLE 44. COMPANY 8: KEY STRATERGIES
- TABLE 45. COMPANY 9: KEY EXECUTIVES
- TABLE 46. COMPANY 9: COMPANY SNAPSHOT
- TABLE 47. COMPANY 9: OPERATING SEGMENTS
- TABLE 48. COMPANY 9: PRODUCT PORTFOLIO
- TABLE 49. COMPANY 9: KEY STRATERGIES
- TABLE 50. COMPANY 10: KEY EXECUTIVES
- TABLE 51. COMPANY 10: COMPANY SNAPSHOT
- TABLE 52. COMPANY 10: OPERATING SEGMENTS
- TABLE 53. COMPANY 10: PRODUCT PORTFOLIO
- TABLE 54. COMPANY 10: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 01. FRANCE RADIOPHARMACEUTICALS MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF FRANCE RADIOPHARMACEUTICALS MARKET, 2022-2032
- FIGURE 03. TOP INVESTMENT POCKETS IN FRANCE RADIOPHARMACEUTICALS MARKET (2023-2032)
- FIGURE 04. PORTER FIVE-1
- FIGURE 05. PORTER FIVE-2
- FIGURE 06. PORTER FIVE-3
- FIGURE 07. PORTER FIVE-4
- FIGURE 08. PORTER FIVE-5
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: FRANCE RADIOPHARMACEUTICALS MARKET
- FIGURE 10. FRANCE RADIOPHARMACEUTICALS MARKET,BY RADIOISOTOPE, 2022 ($MILLION)
- FIGURE 11. FRANCE RADIOPHARMACEUTICALS MARKET,BY APPLICATION, 2022 ($MILLION)
- FIGURE 12. FRANCE RADIOPHARMACEUTICALS MARKET,BY TYPE, 2022 ($MILLION)
- FIGURE 13. FRANCE RADIOPHARMACEUTICALS MARKET,BY END USER, 2022 ($MILLION)
- FIGURE 14. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 18. COMPETITIVE DASHBOARD
- FIGURE 19. COMPETITIVE HEATMAP: FRANCE RADIOPHARMACEUTICALS MARKET
- FIGURE 20. TOP PLAYER POSITIONING, 2022
- FIGURE 21. COMPANY 1: NET SALES, 2020-2022* ($MILLION)
- FIGURE 22. COMPANY 1: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 23. COMPANY 1: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 24. COMPANY 2: NET SALES, 2020-2022* ($MILLION)
- FIGURE 25. COMPANY 2: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 26. COMPANY 2: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 27. COMPANY 3: NET SALES, 2020-2022* ($MILLION)
- FIGURE 28. COMPANY 3: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 29. COMPANY 3: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 30. COMPANY 4: NET SALES, 2020-2022* ($MILLION)
- FIGURE 31. COMPANY 4: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 32. COMPANY 4: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 33. COMPANY 5: NET SALES, 2020-2022* ($MILLION)
- FIGURE 34. COMPANY 5: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 35. COMPANY 5: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 36. COMPANY 6: NET SALES, 2020-2022* ($MILLION)
- FIGURE 37. COMPANY 6: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 38. COMPANY 6: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 39. COMPANY 7: NET SALES, 2020-2022* ($MILLION)
- FIGURE 40. COMPANY 7: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 41. COMPANY 7: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 42. COMPANY 8: NET SALES, 2020-2022* ($MILLION)
- FIGURE 43. COMPANY 8: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 44. COMPANY 8: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 45. COMPANY 9: NET SALES, 2020-2022* ($MILLION)
- FIGURE 46. COMPANY 9: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 47. COMPANY 9: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 48. COMPANY 10: NET SALES, 2020-2022* ($MILLION)
- FIGURE 49. COMPANY 10: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 50. COMPANY 10: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook